Roche: FDA probing counterfeit cancer drug Avastin
Roche Holding AG is working with U.S. authorities to determine the source of counterfeit Avastin, purchased by at least 19 medical practices in the U.S. Roche and the Food and Drug Administration are seeking to prevent the fake cancer drug, which doesn't include the active ingredient bevacizumab, from being distributed further, the company's Genentech unit said in an e-mail late yesterday. The FDA notified the company about the issue in December, said Edward Lang, a spokesman for Roche's South San Francisco, California-based unit.
- How Top-Ranked MA Plans Earn Their Stars
- Readmissions: No Quick Fix to Costly Hospital Challenge
- How Hospitals Can Become 'Upstreamists'
- 4 Ways to Lower the Cost to Collect from Self-Pay Patients
- WellPoint Dominates Nearly Half of Markets, AMA Says
- 4 Tips for Managing Employed Physicians
- CMS Offers Some ACOs $114M for 'Upfront' Costs
- House Calls Key to Pioneer ACO Success
- Ebola: Second TX Nurse Diagnosed After Improper Protective Gear Application
- How Telehealth Pays Off for Providers, Patients